Review anchor
Neuronal acetylcholine receptor subunit alpha-7
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Neuronal acetylcholine receptor subunit alpha-7
CHEMBL2492
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Neuronal acetylcholine receptor subunit alpha-7 as ChEMBL target CHEMBL2492, mapped to UniProt P36544. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2492
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P36544
Neuronal acetylcholine receptor subunit alpha-7
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Neuronal acetylcholine receptor subunit alpha-7 matters
Neuronal acetylcholine receptor subunit alpha-7 is reviewed as Neuronal acetylcholine receptor subunit alpha-7 (UniProt P36544); Neuronal acetylcholine receptor subunit alpha-7 shows late clinical disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block.; 7 linked drugs keep this evidence frame grounded.; the current evidence base includes 10 approved drugs, 2477 compounds, and 540 assays, with lead potency reaching pChEMBL 10.5.
Protein context
Neuronal acetylcholine receptor subunit alpha-7
Neuronal acetylcholine receptor subunit alpha-7 Sequence length is 502 aa.
Review this target as Neuronal acetylcholine receptor subunit alpha-7, mapped to UniProt P36544. Sequence length is 502 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P36544
Protein
Disease context
Alzheimer disease
Neuronal acetylcholine receptor subunit alpha-7 shows late clinical disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABT-126, AQW051, AZD0328.
Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include ABT-126, AQW051, AZD0328, ENCENICLINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
7 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 10 approved drugs, 2477 compounds, and 540 assays for this target. The dominant activity type is KI. CHEMBL2151438 is the current potency anchor at pChEMBL 10.5.
Use CHEMBL2151438 as the tractability anchor when discussing potency (pChEMBL 10.5).
Activity source · ChEMBL 36 via Core Engine
10 approved
pChEMBL 10.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Neuronal acetylcholine receptor subunit alpha-7 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P36544, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why Alzheimer disease is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2477
Total Compounds
540
Total Assays
10
Approved Drugs
IC50: 328.0, KI: 1188.0, EC50: 1021.0, KD: 13.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2151438
|
10.5 | Ki | — |
|
|
No preferred name
CHEMBL3235498
|
10.0 | Ki | — |
|
|
No preferred name
CHEMBL2151570
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL3235495
|
9.6 | Ki | — |
|
|
No preferred name
CHEMBL2151569
|
9.6 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
VARENICLINE
CHEMBL1076903
|
2006 |
|
|
NICOTINE
CHEMBL3
|
1984 |
|
|
ACETYLCHOLINE
CHEMBL667
|
1973 |
Source Header